J. Borland

发表

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects

K. Dooley, C. Flexner, S. Piscitelli, 2013, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

S. Piscitelli, T. Fujiwara, Y. Lou, 2009, Antimicrobial Agents and Chemotherapy.

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

S. Piscitelli, Y. Lou, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

S. Piscitelli, T. Koshiba, J. Borland, 2013, British journal of clinical pharmacology.

Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food

S. Piscitelli, S. Weller, B. Wynne, 2014, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

S. Piscitelli, T. Wajima, P. Patel, 2013, Clinical pharmacology in drug development.

Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics

M. Shelton, Y. Lou, S. Ford, 2006, Journal of acquired immune deficiency syndromes.

the Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease Inhibitors on Effects of Etravirine Alone and with

S. Piscitelli, Y. Lou, T. Wajima, 2011 .

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, J. Borland, Shuguang Chen, 2013, Antimicrobial Agents and Chemotherapy.

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

M. Shelton, C. Ballow, Eric Lewis, 2007, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects

S. Piscitelli, B. Wynne, N. Arya, 2014, Journal of clinical pharmacology.

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, P. Patel, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

S. Piscitelli, Apurva Patel, Y. Lou, 2011, The Journal of antimicrobial chemotherapy.

Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients

S. Piscitelli, T. Fujiwara, Y. Lou, 2009 .

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

S. Piscitelli, S. Weller, B. Wynne, 2016, European Journal of Clinical Pharmacology.

The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects

B. Wynne, J. Humphreys, G. Bowers, 2016, Journal of acquired immune deficiency syndromes.

Relative Bioavailability of a Paediatric Granule Formulation of the HIV Integrase Inhibitor Dolutegravir in Healthy Adult Subjects

S. Piscitelli, T. Wajima, P. Patel, 2014, Antiviral therapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Recurrent upper gastrointestinal hemorrhage in peptic ulcer.

J. Borland, J. L. Borland, W. R. Hancock, 1967, Gastroenterology.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

S. Piscitelli, T. Wajima, J. Borland, 2015, The Annals of pharmacotherapy.

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

S. Piscitelli, J. Rubio, D. Wilfret, 2014, European Journal of Clinical Pharmacology.

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

S. Piscitelli, S. Castellino, I. Goljer, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects

M. Shelton, Ya-Chi Chen, Y. Lou, 2007, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

S. Piscitelli, S. Weller, B. Wynne, 2013, European Journal of Clinical Pharmacology.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

S. Piscitelli, Y. Lou, T. Wajima, 2011, British journal of clinical pharmacology.

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

S. Piscitelli, Y. Lou, T. Wajima, 2010, Journal of acquired immune deficiency syndromes.

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

S. Piscitelli, J. Rubio, A. Yeo, 2014, Pharmacogenomics.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

W. Symonds, J. Borland, I. Song, 2007, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeﬁciency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects (cid:1)

W. Symonds, J. Borland, I. Song, 2007 .

Effect of Fosamprenavir-Ritonavir on the Pharmacokinetics of Dolutegravir in Healthy Subjects

S. Piscitelli, T. Wajima, J. Borland, 2014, Antimicrobial Agents and Chemotherapy.

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

S. Piscitelli, B. Wynne, Mark Johnson, 2014, British journal of clinical pharmacology.

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.